1022958-53-7Relevant academic research and scientific papers
Discovery of an orally efficacious inhibitor of anaplastic lymphoma kinase
Gingrich, Diane E.,Lisko, Joseph G.,Curry, Matthew A.,Cheng, Mangeng,Quail, Matthew,Lu, Lihui,Wan, Weihua,Albom, Mark S.,Angeles, Thelma S.,Aimone, Lisa D.,Haltiwanger, R. Curtis,Wells-Knecht, Kevin,Ott, Gregory R.,Ghose, Arup K.,Ator, Mark A.,Ruggeri, Bruce,Dorsey, Bruce D.
, p. 4580 - 4593 (2012)
Anaplastic lymphoma kinase (ALK) is a promising therapeutic target for the treatment of cancer, supported by considerable favorable preclinical and clinical activities over the past several years and culminating in the recent FDA approval of the ALK inhib
